<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121767</url>
  </required_header>
  <id_info>
    <org_study_id>samsungmc_TTA_edoxaban</org_study_id>
    <nct_id>NCT04121767</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Edoxaban in Thoracoscopic Ablation</brief_title>
  <official_title>Safety and Efficacy of Edoxaban Versus Warfarin in Patients Undergoing a Thoracoscopic Ablation for Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the safety and efficacy of edoxaban and warfarin for&#xD;
      prevention of stroke during a 6-month follow up after total thoracoscopic ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Korea, 5% of patients older than 65 years and 10% of patients older than 80 have a history&#xD;
      of atrial fibrillation (AF), which is often associated with sudden death and stroke.&#xD;
      Medication and percutaneous radiofrequency catheter ablation are commonly used treatment&#xD;
      modalities. Pharmacotherapy is primarily symptomatic treatment; moreover, the effect of&#xD;
      conversion to a normal rhythm is minimal, and mainly aimed at stabilizing heart rate.&#xD;
      Catheter ablation is associated with a high incidence of recurrence in chronic AF, and it is&#xD;
      difficult to treat left atrial appendage, thereby preventing discontinuation of&#xD;
      anticoagulation therapy post procedure. Thoracoscopic ablation is known to be a less invasive&#xD;
      and more effective modality to treat patients with chronic atrial fibrillation. However,&#xD;
      anticoagulation therapy is mandatory in the early postoperative period due to intracardiac&#xD;
      thromboembolism associated with atrial stunning despite conversion to a sinus rhythm and&#xD;
      resection of the left atrial appendage. Further investigation would be required to assess the&#xD;
      efficacy and safety of novel oral anticoagulants such as edoxaban compared to that of&#xD;
      warfarin for stroke prevention during the early postoperative period (6 months) after a&#xD;
      thoracoscopic procedure. The need to maintain a constant level of blood coagulation and the&#xD;
      potential development of complications such as hemorrhages are drawbacks associated with the&#xD;
      use of warfarin. While novel oral anticoagulants such as edoxaban do have a role in atrial&#xD;
      fibrillation, data regarding their effectiveness and incidence of complications after&#xD;
      arrhythmia surgery do not exist. In this study, we will compare warfarin and edoxaban with&#xD;
      respect to safety and efficacy, after they are used for 6 months following thoracoscopic&#xD;
      ablation in patients with chronic atrial fibrillation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">July 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative stroke</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients showing thromboembolic neurologic complication after thoracoscopic ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients showing bleeding events due to anticoagulation after thoracoscopic ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pericarditis</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients showing pericarditis requiring readmission after thoracoscopic ablation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Anticoagulants and Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>Edoxaban group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients prescribed edoxaban after thoracoscopic ablation during window period to prevent stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients prescribed warfarin after thoracoscopic ablation during window period to prevent stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>oral edoxaban 60mg once daily for 3 months</description>
    <arm_group_label>Edoxaban group</arm_group_label>
    <other_name>Savaysa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>oral warfarin once daily for 3 months according to prothrombin time</description>
    <arm_group_label>Warfarin group</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 years or older (not exceed 80 years old).&#xD;
&#xD;
          2. Elective thoracoscopic ablation.&#xD;
&#xD;
          3. Presence of atrial fibrillation (paroxysmal, persistent, long-standing persistent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic obstructive pulmonary disease (COPD).&#xD;
&#xD;
          2. History of pulmonary tuberculosis.&#xD;
&#xD;
          3. Other cardiac comorbidities including valvular disease, coronary artery disease.&#xD;
&#xD;
          4. Congenital heart anomalies except for atrial septal defect.&#xD;
&#xD;
          5. Known, clinically important anemia or thrombocytopenia.&#xD;
&#xD;
          6. Pregnancy or lactation.&#xD;
&#xD;
          7. Malignancy.&#xD;
&#xD;
          8. Intracardiac mass or thrombus&#xD;
&#xD;
          9. Life expectancy less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Seop Jeong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Dong Seop Jeong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>thoracoscopic ablation</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

